To tackle the public health crisis of Alzheimer’s disease (AD), we must work together. The Charleston Conference on Alzheimer’s Disease (CCAD) partners with over 50 universities across the United States to help ensure early-career scientists are collaborating, advancing their research and successfully pursuing funding opportunities for their innovative ideas.
CCAD has provided seed funding to over twenty early-career investigators who have gone on to receive significant NIH grants – boosting their careers and bringing prestige to their institutions. Also, CCAD attendees have subsequently collaborated to secure additional funding together.
CCAD and its parent company, New Vision Research, hopes cross-pollination among scientists from different educational institutions and organizations helps lead to improvements in diagnosis and treatment, and ultimately a cure for Alzheimer’s disease.